menu
    • menu
    [{"orgOrder":0,"company":"Columbia University","sponsor":"Fortress Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"ONCOlogues","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Columbia University \/ Fortress Biotech ","highestDevelopmentStatusID":"1","companyTruncated":"Columbia University \/ Fortress Biotech "},{"orgOrder":0,"company":"Columbia University","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccines","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Columbia University \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Columbia University \/ Tonix Pharmaceuticals"},{"orgOrder":0,"company":"Columbia University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sofosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Columbia University \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Columbia University \/ Not Applicable"},{"orgOrder":0,"company":"Columbia University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Coronavirus-neutralising antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Columbia University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Columbia University \/ Not Applicable"},{"orgOrder":0,"company":"Columbia University","sponsor":"Oryzon Genomics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Columbia University \/ Oryzon Genomics","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Oryzon Genomics"},{"orgOrder":0,"company":"Columbia University","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"ADXS-504","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Columbia University \/ Advaxis","highestDevelopmentStatusID":"5","companyTruncated":"Columbia University \/ Advaxis"},{"orgOrder":0,"company":"Columbia University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Convalescent plasma","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Columbia University \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Not Applicable"},{"orgOrder":0,"company":"Columbia University","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Expanded Collaboration","leadProduct":"TNX-1800","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Percutaneous","sponsorNew":"Columbia University \/ Columbia University","highestDevelopmentStatusID":"5","companyTruncated":"Columbia University \/ Columbia University"},{"orgOrder":0,"company":"Columbia University","sponsor":"Silo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Columbia University \/ Columbia University","highestDevelopmentStatusID":"4","companyTruncated":"Columbia University \/ Columbia University"},{"orgOrder":0,"company":"Columbia University","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Columbia University \/ Columbia University","highestDevelopmentStatusID":"2","companyTruncated":"Columbia University \/ Columbia University"},{"orgOrder":0,"company":"Columbia University","sponsor":"RenovoRx","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase III","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Columbia University \/ Columbia University","highestDevelopmentStatusID":"10","companyTruncated":"Columbia University \/ Columbia University"},{"orgOrder":0,"company":"Columbia University","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"ADXS-504","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Columbia University \/ Columbia University Irving Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Columbia University \/ Columbia University Irving Medical Center"},{"orgOrder":0,"company":"Columbia University","sponsor":"Actinium pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Cladribine","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Columbia University \/ Columbia University","highestDevelopmentStatusID":"7","companyTruncated":"Columbia University \/ Columbia University"},{"orgOrder":0,"company":"Columbia University","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"TNX-3600","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Columbia University \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"4","companyTruncated":"Columbia University \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Columbia University","sponsor":"TFC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Columbia University \/ Columbia University","highestDevelopmentStatusID":"2","companyTruncated":"Columbia University \/ Columbia University"},{"orgOrder":0,"company":"Columbia University","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Columbia University \/ Columbia University","highestDevelopmentStatusID":"10","companyTruncated":"Columbia University \/ Columbia University"},{"orgOrder":0,"company":"Columbia University","sponsor":"Actinium pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Apamistamab-I-131","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Columbia University \/ Columbia University","highestDevelopmentStatusID":"14","companyTruncated":"Columbia University \/ Columbia University"},{"orgOrder":0,"company":"Columbia University","sponsor":"Sable Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"SBL-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Columbia University \/ Columbia University","highestDevelopmentStatusID":"14","companyTruncated":"Columbia University \/ Columbia University"}]

    Find Clinical Drug Pipeline Developments & Deals by Columbia University

    Menu

    Columbia University

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SBL-001

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Preclinical

                            Recipient : Sable Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sable Therapeutics and Columbia Sign Deal on Obesity Treatments

                            Details : The collaboration will advance a portfolio of novel polycation nanomedicines, designated as SBL-001 and SBL-002, intended to treat visceral and subcutaneous adiposity.

                            Brand Name : SBL-001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 12, 2024

                            Lead Product(s) : SBL-001

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Preclinical

                            Recipient : Sable Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apamistamab-I-131

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Recipient : Actinium pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Actinium Gets FDA Clearance for Iomab-ACT IND Targeting Sickle Cell Disease Conditioning

                            Details : The collaboration aims to advance the development of Iomab-ACT (Apamistamab-I-131) and to evaluate the safety of Iomab-ACT in patients with sickle cell disease who are to receive an allogeneic BMT.

                            Brand Name : Iomab-ACT

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 25, 2024

                            Lead Product(s) : Apamistamab-I-131

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Recipient : Actinium pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Recipient : NRx Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University A...

                            Details : Through the agreement, NRx will focus on the NRX-100 (ketamine HCl), NMDA 3A inhibitor. It is being evaluated in Phase III clinical trial studies with patients for the treatment of Bipolar Depression and related to Suicidal Ideation.

                            Brand Name : NRX-100

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 19, 2023

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Recipient : NRx Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : TFC Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            TFC Therapeutics Launches to Advance Novel Platform and Technologies in Cancer Biology

                            Details : The agreement aims to develop a drug discovery platform that targets Tumor Macrophage Hybrid (TMH) cells to eliminate the most resilient cancers and stop disease recurrence.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 17, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : TFC Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TNX-3600

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Tonix Pharmaceuticals Holding Corp

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Mur...

                            Details : Under the licensing agreement, Tonix will develop a portfolio of fully human (TNX-3600) and murine (TNX-4100) mAbs for the treatment or prophylaxis of SARS-CoV-2 infection. TNX-3600 are generated from SARS-CoV-2+ asymptomatic individuals or COVID-19 conv...

                            Brand Name : TNX-3600

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 13, 2023

                            Lead Product(s) : TNX-3600

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Tonix Pharmaceuticals Holding Corp

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lintuzumab-Ac225,Cladribine,Cytarabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Actinium pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Actinium Pharmaceuticals, Inc. Announces Research Collaboration with Columbia University to Study Actimab-A in...

                            Details : Actimab-A (lintuzumab-Ac-225) is an Actinium-225 based antibody radiation conjugate targeting CD33, a validated target that is expressed in virtually all patients with AML. Actimab-A due to its radiation modality is agnostic to cytogenetics.

                            Brand Name : Actimab-A

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 08, 2022

                            Lead Product(s) : Lintuzumab-Ac225,Cladribine,Cytarabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Actinium pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADXS-504

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Ayala Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Advaxis Updates on PI Trial of ADXS-504 for Early Prostate Cancer

                            Details : ADXS-504 is a novel Lm-based immunotherapy, bioengineered to elicit T cell responses against 24 tumor antigens, including 14 peptide antigens derived from hotspot mutations in patients with prostate cancer.

                            Brand Name : ADXS-504

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            June 29, 2022

                            Lead Product(s) : ADXS-504

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Ayala Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : RenovoRx

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University’s New York-Presbyterian Hospital Irv...

                            Details : RenovoRx’s lead product candidate, RenovoGem, is a combination of gemcitabine and the patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC).

                            Brand Name : Gemzar

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 22, 2022

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : RenovoRx

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : BridgeBio Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BridgeBio Pharma Collaborates with Columbia University & Mount Sinai to Develop Potential Therapies for Geneti...

                            Details : BridgeBio has initiated 25 collaborations with leading institutions around the world that are focused on providing therapeutic options to patients with unmet need as quickly and safely as possible.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 29, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : BridgeBio Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Columbia University

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Silo Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeut...

                            Details : Under the agreement, Silo has been granted an option to license psychedelics as a therapeutic currently under development, for Alzheimer’s disease.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 27, 2021

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Silo Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth